Quotes 5-day view Delayed London Stock Exchange
04/12/2021
04/13/2021
04/14/2021
04/15/2021
04/16/2021
Date
7225(c)
7167(c)
7271(c)
7400(c)
7380(c)
Last
1 338 070
1 581 490
1 789 183
2 424 504
2 536 841
Volume
-0.85% -0.80% +1.45% +1.77% -0.27% Change
Sales 2021
30 805 M - -
Net income 2021
5 064 M - -
Net Debt 2021
11 692 M - -
P/E ratio 2021
26,1x
Yield 2021
2,79%
Sales 2022
35 117 M - -
Net income 2022
6 489 M - -
Net Debt 2022
9 676 M - -
P/E ratio 2022
18,9x
Yield 2022
2,89%
Capitalization
134 B 134 B -
EV / Sales 2021
4,73x
EV / Sales 2022
4,09x
Nbr of Employees
76 100
Free-Float
95,8%
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (97.3%). Net sales break down by treatment area between oncology (41.9%), cardiovascular, renal and metabolic diseases (27.4%), respiratory and autoimmune diseases (20.7%), and other (10%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
-...
Notations Surperformance© of AstraZeneca PLC
Trading Rating : Investor Rating :
All news about ASTRAZENECA PLC
News in other languages on ASTRAZENECA PLC
Analyst Recommendations on ASTRAZENECA PLC
Equities, oil prices fall on concerns over Europe COVID-19 surge
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ASTRAZENECA PLC
Short Term Mid-Term Long Term Trends Bullish Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
25
Average target price
129,60 $
Last Close Price
102,07 $
Spread / Highest target
62,6%
Spread / Average Target
27,0%
Spread / Lowest Target
-7,74%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Nederland
Schweiz (DE)
United Kingdom
Report
